265652-38-8

Basic information

• Product Name: methyl 4-bromo-3-methylthiophene-2-carboxylate
• Synonyms: methyl 4-bromo-3-methylthiophene-2-carboxylate;4-bromo-3-methyl-2-Thiophenecarboxylic acid methyl ester;4-Bromo-3-methyl-thiophene-2-carboxylic acid methyl ester
• CAS NO: 265652-38-8
• Molecular Formula: C₇H₇BrO₂S
• Molecular Weight: 235.09828
• EINECS: -0
• Mol File: 265652-38-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 61-61.5 °C
• Boiling Point: 263.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.575±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl 4-bromo-3-methylthiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-bromo-3-methylthiophene-2-carboxylate(265652-38-8)
• EPA Substance Registry System: methyl 4-bromo-3-methylthiophene-2-carboxylate(265652-38-8)

Safety Data

• Hazardous Substances Data: 265652-38-8(Hazardous Substances Data)

Upstream product

• 95201-93-7 methyl 3-hydroxy-4-bromo-2-thiophenecarboxylate 
• 863906-40-5 methyl 4-bromo-3-([(trifluoromethyl)sulfonyl]oxy)-2-thiophenecarboxylate 
• 13061-96-6 dihydroxy-methyl-borane 
• 5118-06-9 methyl 3-hydroxy-2-thiophenecarboxylate 
• 23806-24-8 3-methyl-2-thiophenecarboxylic acid 
• 265652-39-9 3-methyl-4-bromo-2-thiophenecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 81452-54-2 methyl 3-methylthiophene-2-carboxylate 
• 186581-53-3 diazomethane 

Downstream Products

• 1373940-62-5 4-bromo-N-(2,6-difluorophenyl)-3-methylthiophene-2-carboxamide 
• 265652-39-9 3-methyl-4-bromo-2-thiophenecarboxylic acid 
• 1398414-42-0 C₁₉H₁₇NO₃S 

Relevant articles and documents

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this ne

METHODS OF TREATING NEURODEGENERATIVE DISEASES

Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.

COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.